Business
If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep...
Cathie Wood is buying up stocks from the most dubious actors in the psychedelic sector. Given ARK Invest’s subpar performance,...
The psychedelic renaissance hits a rough patch as major companies look to tighten their belts or face total collapse. What’s...
MindMed drops its proprietary ibogaine for opioid addiction research amidst an ongoing shakeup. What is going on with this psychedelics...
Field Trip is the only company exploring the therapeutic potential of a 4-HO-DiPT prodrug called FT-104. But how does it...
Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property...
In a rare move Cybin aquires a phase 1 DMT clinical trial from Entheon Biomedical. CEO Doug Drysdale explains why...
Project Solace uses real-world data to inform development of regulated psilocybin therapy, led by Canadian non-profit TheraPsil...
Does microdosing psychedelics work, or is it the placebo effect? Here are 3 microdosing clinical trials looking for answers...
Compass Pathways and Small Pharma announce executive shakeup, Mydecine and Awakn push forward with new research...